Abstract
Androgen receptors have been shown to play a critical role in prostate cancer. We used ultrasound imaging techniques to track tumor response to antiandrogen and rapamycin treatment in a prostate-specific Pten-deleted mouse model of cancer. Depletion of androgens by either surgical or chemical castration significantly inhibited tumor growth progression without altering the activation of Akt and mammalian target of rapamycin (mTOR). We also showed for the first time that targeting mTOR along with antiandrogen treatment exhibited additive antitumor effects in vivo when compared with single agents. Our preclinical data suggest that combination of antiandrogens with mTOR inhibitors might be more effective in treating androgen-dependent prostate cancer patients.
MeSH terms
-
Androgen Antagonists / administration & dosage
-
Androgen Antagonists / pharmacology*
-
Animals
-
Antineoplastic Combined Chemotherapy Protocols / pharmacology*
-
Carrier Proteins / metabolism*
-
Cell Growth Processes / drug effects
-
Imaging, Three-Dimensional / methods
-
Male
-
Mice
-
Mice, Inbred C57BL
-
Mice, Inbred DBA
-
Oncogene Protein v-akt / metabolism
-
PTEN Phosphohydrolase / deficiency
-
PTEN Phosphohydrolase / genetics
-
Phosphotransferases (Alcohol Group Acceptor) / metabolism*
-
Prostatic Neoplasms / diagnostic imaging
-
Prostatic Neoplasms / drug therapy*
-
Prostatic Neoplasms / pathology
-
Sirolimus / administration & dosage
-
Sirolimus / pharmacology*
-
TOR Serine-Threonine Kinases
-
Ultrasonography / methods
Substances
-
Androgen Antagonists
-
Carrier Proteins
-
Phosphotransferases (Alcohol Group Acceptor)
-
mTOR protein, mouse
-
Oncogene Protein v-akt
-
TOR Serine-Threonine Kinases
-
PTEN Phosphohydrolase
-
Pten protein, mouse
-
Sirolimus